Skip to content

AARD AARD Other operating expenses

Other operating expenses at other companies

Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$19.46M+6.8%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$164.13M+196%
Arvinas logo
ArvinasARVN
$79.4M-32.4%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$60.02M+26.0%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$151M+0.7%

Other financials

Income statement

See full
Revenue-
Operating income-$22.5M-115%
Net income-$21.6M-132%
EPS (diluted)-$0.99-39.4%

Balance sheet

See full
Cash & equivalents$62.4M+136%
Total debt$336.0K-53.7%
Total equity$87.0M-42.3%
Total assets$98.6M-37.2%

Cash flow

See full
Operating cash flow-$18.9M-65.7%
CapEx--100%
Free cash flow-$16.8M-117%

Valuation

See full
Market cap$124.35M-58.6%
Enterprise value$62.25M-77.4%

Returns & leverage

See full
Return on equity-58.8%
Debt / equity0.0×
Current ratio8.1×-17.8×

Where this comes from

Reported directly by AARD in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The official record: AARD’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about AARD's other operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AARD's other operating expenses?
AARD (AARD) reported other operating expenses of $22.46M in Q1 2026.
How has AARD's other operating expenses changed year-over-year?
AARD's other operating expenses increased by 114.6% year-over-year, from $10.47M to $22.46M.
What does other operating expenses mean?
Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.